AstraZeneca: Farxiga achieved a positive result in the Phase III DECLARE-TIMI 58 trial, a large cardiovascular outcomes trial in 17,000 patients with type-2 diabetes Guest UserOctober 7, 2018 Facebook0 Twitter LinkedIn0 0 Likes